These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 646327)

  • 1. Combinations of cytotoxic agents that have less than expected toxicity on normal tissues in mice.
    Millar JL; McElwain TJ
    Antibiot Chemother (1971); 1978; 23():271-82. PubMed ID: 646327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased tolerance to dimethyl-myleran, cyclophosphamide and radiation in lymphoma-bearing mice.
    Floersheim GL
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):777-84. PubMed ID: 6759142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan.
    Millar JL; Hudspith BN; Blackett NM
    Br J Cancer; 1975 Aug; 32(2):193-8. PubMed ID: 764844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stem-cell survival and tumor control in the Lewis lung carcinoma.
    Steel GG; Adams K
    Cancer Res; 1975 Jun; 35(6):1530-5. PubMed ID: 1169108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Combination chemotherapy of tumors (an experimental study)].
    Stukov AN
    Vopr Onkol; 1975; 21(3):65-9. PubMed ID: 805499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The value of combining the radiosensitizer misonidazole with cyclophosphamide in treating the murine Lewis lung tumor.
    Pedersen JE; Barron G; Meeker BE
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):651-3. PubMed ID: 7107392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.
    Evans BD; Smith IE; Millar JL
    Br J Cancer; 1983 Feb; 47(2):215-9. PubMed ID: 6297529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of micrometastases from Lewis lung carcinoma with abrin and cyclophosphamide, given singly and in combination.
    Gundersen S; Fodstad O
    Int J Cancer; 1979 Apr; 23(4):530-5. PubMed ID: 437927
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sensitivity to cytotoxic agents of the EMT6 tumour in vivo: tumour volume versus in vitro plating. 1. Cyclophosphamide.
    Twentyman PR
    Br J Cancer; 1977 Feb; 35(2):208-17. PubMed ID: 836758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mixed effects of 2,6-dithiopurine against cyclophosphamide mediated bladder and lung toxicity in mice.
    Datta K; Chin A; Ahmed T; Qing WG; Powell KL; Simhambhatla P; MacLeod MC; Stoica G; Kehrer JP
    Toxicology; 1998 Jan; 125(1):1-11. PubMed ID: 9585095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adriamycin/cyclophosphamide combination chemotherapy: the importance of drug scheduling.
    Mulder JH; van Putten LM
    Eur J Cancer (1965); 1979 Dec; 15(12):1503-9. PubMed ID: 294960
    [No Abstract]   [Full Text] [Related]  

  • 12. The effect of granulocyte-macrophage colony-stimulating factor (GM-CSF) on primitive hematopoietic stem cell (PHSC) function and numbers, after chemotherapy.
    Gardner RV; Begue R; McKinnon E
    Exp Hematol; 2001 Sep; 29(9):1053-9. PubMed ID: 11532345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cautionary tale: how to delete mouse haemopoietic stem cells with busulphan.
    Jopling C; Rosendaal M
    Br J Haematol; 2001 Jun; 113(4):970-4. PubMed ID: 11442491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide and iphosphamide against Lewis lung carcinoma: evaluation of toxic and therapeutic effects.
    Greco C; Corsi A; Caputo M; Cavallari A; Calabresi F
    Tumori; 1979 Apr; 65(2):169-80. PubMed ID: 462569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancement of cyclophosphamide cytotoxicity in vivo by the benzamide analogue pyrazinamide.
    Horsman MR; Chaplin DJ
    Br J Cancer; 1994 Apr; 69(4):648-54. PubMed ID: 8142253
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of RIP1 and RIP3 in the development of aplastic anemia induced by cyclophosphamide and busulphan in mice.
    Chen YF; Zhao ZQ; Wu ZM; Zou ZY; Luo XJ; Li J; Xie C; Liang Y
    Int J Clin Exp Pathol; 2014; 7(12):8411-20. PubMed ID: 25674205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: time interval influence on therapeutic efficacy and therapy-related toxicity.
    Hassan M; Ljungman P; Ringdén O; Hassan Z; Oberg G; Nilsson C; Békassy A; Bielenstein M; Abdel-Rehim M; Georén S; Astner L
    Bone Marrow Transplant; 2000 May; 25(9):915-24. PubMed ID: 10800057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined effect of levan and cytotoxic agents on the growth of experimental tumours in mice.
    Leibovici J; Stark Y; Wolman M
    Br J Exp Pathol; 1983 Jun; 64(3):239-44. PubMed ID: 6882675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interactions in recovery and in residual injury from sequential treatments of mouse haemopoietic and stromal marrow cell populations, using X-rays, cyclophosphamide and busulphan.
    Qi DY; Hendry JH; Testa NG
    Radiother Oncol; 1991 Jan; 20(1):46-52. PubMed ID: 2020755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison in vivo of the clastogenic properties of busulfan and cyclophosphamide].
    Léonard A; Deknudt G
    C R Seances Soc Biol Fil; 1983; 177(2):239-42. PubMed ID: 6224545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.